These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 9134073)
1. Pergolide mesylate. Adverse events occurring in the treatment of cocaine dependence. Malcolm R; Moore JW; Kajdasz DK; Cochrane CE Am J Addict; 1997; 6(2):117-23. PubMed ID: 9134073 [TBL] [Abstract][Full Text] [Related]
2. Pergolide mesylate for cocaine abuse: a controlled preliminary trial. Levin FR; McDowell D; Evans SM; Brooks D; Spano C; Nunes EV Am J Addict; 1999; 8(2):120-7. PubMed ID: 10365192 [TBL] [Abstract][Full Text] [Related]
3. A double-blind, placebo-controlled outpatient trial of pergolide for cocaine dependence. Malcolm R; Kajdasz DK; Herron J; Anton RF; Brady KT Drug Alcohol Depend; 2000 Aug; 60(2):161-8. PubMed ID: 10940543 [TBL] [Abstract][Full Text] [Related]
4. Adverse outcomes in a controlled trial of pergolide for cocaine dependence. Malcolm R; Herron J; Sutherland SE; Brady KT J Addict Dis; 2001; 20(1):81-92. PubMed ID: 11286433 [TBL] [Abstract][Full Text] [Related]
5. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease. Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211 [TBL] [Abstract][Full Text] [Related]
7. Use of dopamine agonist pergolide in outpatient treatment of cocaine dependence. Focchi GR; Leite MC; Andrade AG; Scivoletto S Subst Use Misuse; 2005; 40(8):1169-77. PubMed ID: 16040376 [TBL] [Abstract][Full Text] [Related]
8. [Multiple latency test in a patient with episodes of sleep induced by pergolide]. Jiménez-Jiménez FJ; Velasco I; de Toledo M; Sayed Y; Zurdo J; Ortí-Pareja M Rev Neurol; 2002 Jun 16-30; 34(12):1140-1. PubMed ID: 12134281 [TBL] [Abstract][Full Text] [Related]
13. Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy. Comella CL; Morrissey M; Janko K Neurology; 2005 Apr; 64(8):1450-1. PubMed ID: 15851743 [TBL] [Abstract][Full Text] [Related]
14. Trial of subtherapeutic pergolide in de novo Parkinson's disease. Grosset K; Grosset D; Lees A; Mov Disord; 2005 Mar; 20(3):363-6. PubMed ID: 15580607 [TBL] [Abstract][Full Text] [Related]
15. Pergolide and Parkinson's disease: new preparation. No clear benefit. Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497 [TBL] [Abstract][Full Text] [Related]
16. High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study. Arnold G; Gasser T; Storch A; Lipp A; Kupsch A; Hundemer HP; Schwarz J Arch Gerontol Geriatr; 2005; 41(3):239-53. PubMed ID: 16029905 [TBL] [Abstract][Full Text] [Related]
17. [Pergolide: a useful agonist for the treatment of Parkinson disease]. Bonnet AM; Houeto JL Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908 [TBL] [Abstract][Full Text] [Related]
18. Pergolide to augment the effectiveness of antidepressants: clinical experience and a small double-blind study. Mattes JA Ann Clin Psychiatry; 1997 Jun; 9(2):87-8. PubMed ID: 9242894 [TBL] [Abstract][Full Text] [Related]
19. Switching from pergolide to pramipexole in patients with Parkinson's disease. Hanna PA; Ratkos L; Ondo WG; Jankovic J J Neural Transm (Vienna); 2001; 108(1):63-70. PubMed ID: 11261747 [TBL] [Abstract][Full Text] [Related]
20. Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor. Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG Mov Disord; 2003 Nov; 18(11):1324-31. PubMed ID: 14639675 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]